Table 1

. Inclusion and exclusion criteria for the systematic review

Inclusion criteria

  1. Adult patients with nAMD

  2. One-year results on the efficacy and safety of monotherapy with faricimab 6 mg, ranibizumab 0.5 mg, aflibercept 2 mg, brolucizumab 6 mg and bevacizumab 1.25 mg, with or without LD and both fixed and flexible regimens

  3. Phase II and III RCT available as a complete publication

  4. RCT where the comparison arms included at least two of the treatments and doses mentioned above

Exclusion criteria

  1. Studies conducted in patients with polypoidal choroidal vasculopathy (differential diagnosis of nAMD)

  2. Studies evaluating one anti-VEGF vs combination therapy (anti-VEGF plus photodynamic therapy (PDT) or plus intravitreal steroids).

  • In studies with more than two arms, where the evaluated arms included anti-VEGF combined therapies or non-anti-VEGF treatments, including PDT and intravitreal steroids, only the anti-VEGF arms monotherapies were included; the additional arms were excluded of the analysis, in accordance with the NICE technical support document.88

  • LD, loading dose; nAMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; RCT, randomised controlled trial; VEGF, vascular endothelial growth factor.